Lipid Nanoparticles (LNPs)
Besides the mRNA optimized construction and manufacturing, the efficient intracellular delivery of mRNA-based drugs is another significant research area, and much effort has been made in choosing and optimizing proper delivery vectors. To date, one of the most developed methods for mRNA delivery is co-formulation into lipid nanoparticles (LNPs). Creative Biogene is committed to creating services according to our customer's research goals. We can design and produce LNPs for mRNA delivery and screen administration routes. With extensive experience in the field of mRNA delivery and constant optimization exploration, we are confident to provide the best quality service at the most competitive price.
Why choose lipid nanoparticles
Fig.1 mRNA LNPs formulation. (Verbeke, R., et al, 2019)
LNPs are liposome-like structures and the first use of LNPs as a delivery vector for mRNA was reported in 2015. As the most commonly used material for non-viral mRNA delivery, various synthetic and naturally-derived lipids have been employed to form LNPs. It is widely accepted that LNPs are internalized by endocytosis and subsequently attach electrostatically and fuse with the cell membrane using inverted non-bilayer lipid phases, although the mechanism of LNP-mediated delivery of mRNA is not fully understood. By encapsulating mRNA within a LNPs, the method not only physically protects mRNA against enzymatic degradation conditions, but also allows mRNA to alter its biodistribution, cellular targeting and cellular uptake mechanism, thereby contributing to the delivery of mRNA and mRNA-based drug outcome. In addition, the application of established DNA and siRNA delivery systems has partly facilitated the use of nanoparticles in mRNA delivery.
Service in Creative Biogene
Design and production of LNPs for mRNA delivery
The physicochemical and structural characteristics of mRNA LNPs will depend on lipid composition, the ratio of mRNA to the total amount of (cationic/ ionizable) lipids, and the LNPs synthesis. Based on deep and broad expertise in the targeted delivery of mRNA, we use combinatorial methods to identify novel compounds and optimize formulations for mRNA delivery vectors. Our delivery platform offers high encapsulation efficiency with greater payload capacity and supports a broad variety of cells or tissues. In addition, we focus on service quality, speed, cost, to ensure that the intracellular mRNA delivery is supported in the most effective way.
Fig.2 Schematic representation of the mechanism driving the self-assembly of mRNA-loaded lipid nanoparticles.
Screening of administration route
With years of continuous research, we have developed an administration route screening platform based on advanced technologies. Our screening platform contains a series of commonly applied therapeutic delivery routes, such as intravenous (IV) administration, intramuscular (IM) administration and subcutaneous delivery. In addition, we also provide further custom LNPs formation optimization services, specific administration route needs, involving regulating the particle size, modifying their helper lipid composition as well as addition of targeting ligands.
Creative Biogene is passionate about strong customer orientation and high-quality service. We continuously challenge ourselves to stay ahead and remain one of the leading mRNA delivery service providers worldwide. If you are interested in our services, please contact us for more information.
- Kowalski, P. S., et al. (2019). "Delivering the messenger: advances in technologies for therapeutic mRNA delivery." Molecular Therapy, 27(4), 710-728.
- Verbeke, R., et al. (2019). "Three decades of messenger RNA vaccine development." Nano Today, 28, 100766.